Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Diuretics in primary hypertension - Reloaded.

Mishra S.

Indian Heart J. 2016 Sep - Oct;68(5):720-723. doi: 10.1016/j.ihj.2016.08.013. Epub 2016 Sep 10.

2.

Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Gomez-Sanchez EP.

J Cardiovasc Pharmacol. 2016 Jan;67(1):26-38. doi: 10.1097/FJC.0000000000000329. Review.

3.

Central integration and neural control of blood pressure during the cold pressor test: a comparison between hydrochlorothiazide and aliskiren.

Jarvis SS, Okada Y, Levine BD, Fu Q.

Physiol Rep. 2015 Sep 14;3(9). pii: e12502. doi: 10.14814/phy2.12502. Epub 2015 Sep 15.

4.

Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic.

Vongpatanasin W.

Curr Opin Cardiol. 2015 Jul;30(4):361-5. doi: 10.1097/HCO.0000000000000178. Review.

5.
6.

Gene mutations that promote adrenal aldosterone production, sodium retention, and hypertension.

Moraitis AG, Rainey WE, Auchus RJ.

Appl Clin Genet. 2013 Dec 24;7:1-13. doi: 10.2147/TACG.S35571. Review.

7.

Essential hypertension: an approach to its etiology and neurogenic pathophysiology.

BolĂ­var JJ.

Int J Hypertens. 2013;2013:547809. doi: 10.1155/2013/547809. Epub 2013 Dec 9. Review.

8.

Effects of sex and hypertension subtype on haemodynamics and left ventricular diastolic function in older patients with stage 1 hypertension.

Fujimoto N, Okada Y, Shibata S, Best SA, Bivens TB, Levine BD, Fu Q.

J Hypertens. 2013 Nov;31(11):2282-9; discussion 2289. doi: 10.1097/HJH.0b013e3283649730.

9.

Chronic renin inhibition lowers blood pressure and reduces upright muscle sympathetic nerve activity in hypertensive seniors.

Okada Y, Jarvis SS, Best SA, Bivens TB, Adams-Huet B, Levine BD, Fu Q.

J Physiol. 2013 Dec 1;591(23):5913-22. doi: 10.1113/jphysiol.2013.261362. Epub 2013 Sep 23.

10.

The ubiquitous mineralocorticoid receptor: clinical implications.

Hawkins UA, Gomez-Sanchez EP, Gomez-Sanchez CM, Gomez-Sanchez CE.

Curr Hypertens Rep. 2012 Dec;14(6):573-80. doi: 10.1007/s11906-012-0297-0. Review.

11.

Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.

Raheja P, Price A, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Vongpatanasin W.

Hypertension. 2012 Aug;60(2):319-25. doi: 10.1161/HYPERTENSIONAHA.112.194787. Epub 2012 Jun 25.

12.

Pathophysiology of resistant hypertension: the role of sympathetic nervous system.

Tsioufis C, Kordalis A, Flessas D, Anastasopoulos I, Tsiachris D, Papademetriou V, Stefanadis C.

Int J Hypertens. 2011 Jan 20;2011:642416. doi: 10.4061/2011/642416.

13.

Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism.

Kontak AC, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Nesbitt SD, Victor RG, Vongpatanasin W.

J Clin Endocrinol Metab. 2010 Oct;95(10):4756-61. doi: 10.1210/jc.2010-0823. Epub 2010 Jul 21.

14.

Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension.

Wray DW, Supiano MA.

Hypertension. 2010 May;55(5):1217-23. doi: 10.1161/HYPERTENSIONAHA.109.147058. Epub 2010 Apr 5.

15.

Therapeutic strategies for targeting excessive central sympathetic activation in human hypertension.

Fisher JP, Fadel PJ.

Exp Physiol. 2010 May;95(5):572-80. doi: 10.1113/expphysiol.2009.047332. Epub 2010 Mar 19.

16.

Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.

Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-Dehoff RM, Schwartz GL, Bailey K, Chapman A, Hall KL, Feng H, Boerwinkle E, Johnson JA, Gums JG.

Pharmacotherapy. 2009 Oct;29(10):1157-65. doi: 10.1592/phco.29.10.1157.

Supplemental Content

Support Center